Project Grant R01CA288535
Award Date
1/7/25
Completion Date
12/31/29
Dollars Obligated
$418K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $420,251 to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Incorporated) to develop an encapsulated cell-based oncolytic virus therapy for brain tumors. The project aims to enhance the therapeutic efficacy of oncolytic herpes simplex virus delivered...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct a Phase I clinical trial evaluating the safety and feasibility of CARV3.TEAM-E cells for the treatment of primary or recurrent glioblastoma (GBM), a deadly brain tumor. The CARV3.TEAM-E cells are genetically engineered chimeric antigen receptor (CAR) T cells that target the...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
The National Cancer Institute (NCI) awarded Creative Biotherapeutics LLC a $1.2M project grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The research aims to create a non-toxic therapeutic alternative that can increase overall survival and complete response rates for patients with recurrent, drug-resistant brain tumors and brain metastases. Key project objectives include designing inhibitors to...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $633,656 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Brigham & Women's Hospital Inc. to improve intratumoral IL12 immunogene therapy for glioblastoma based on human clinical trial results. The project aims to: 1) compare the efficacy, tolerability, and immune effects of neoadjuvant vs. adjuvant anti-PD1 therapy in mouse models of glioblastoma treated...
This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...
The National Cancer Institute (NCI) awarded a $1,064,642 Project Grant (CFDA 93.396 - Cancer Biology Research) to Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) to characterize the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) signaling axis in regulating glioma stem cell (GSC) properties and glioblastoma (GBM) recurrence. The research aims to elucidate the mechanism by which the ANG-PLXNB2-tRNA-derived small RNA (TRNA) pathway maintains GSC stemness and...
This Project Grant award of $687,279 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to dissect the cellular composition and functional dynamics of the glioblastoma (GBM) tumor microenvironment. The award to Beth Israel Deaconess Medical Center will leverage patient samples and mouse models to investigate how standard-of-care treatments, including...
This federal Project Grant award of $513,859, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to develop a novel adoptive cellular therapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The goal is to generate a continuously renewing population of CAR-expressing natural killer (NK) cells that can provide long-term, safe, and efficacious anti-cancer immunity. The research aims to...